Mental patients and their profile of compliance with psychopharmacological treatment;Los enfermos mentales y su perfil de adhesión al tratamiento psicofarmacológico

Revista da Escola de Enfermagem

Volumn 43, Issue 1, 2009, Pages 154-160

  Cardoso, Lucilene ^a   Galera, Sueli Aparecida Frari ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Community psychiatry; Mentaly ill persons; Patient compliance; Psychiatric nursing; Treatment refusal

Indexed keywords

EID: 69349093431     PISSN: 00806234     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0080-62342009000100021     Document Type: Article

References (18)

1. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Saúde mental no SUS: os centros de atenção psicossocial [texto na Internet]. Brasília; 2004. [citado 2007 nov. 23]. Disponível em: http//www.ccs.saude.gov.br/saude_mental/pdf/SM_Sus.pdf
2. Whitehorn D, Richard JC, Kopala LC. Hospitalization in the first year of treatment for schizophrenia. Can J Psychiatry. 2004; 49(9):635-8.
3. Shirakawa I. Aspectos gerais do manejo do tratamento de pacientes com esquizofrenia. Rev Bras Psiquiatr. 2000;22 Supl 1:56-8.
4. Gray R, Wykes T, Gournay K. From compliance to concordance: a review of the literature on interventions to enhance compliance with antipschotic medication. J Psychiatr Ment Health Nurs. 2002;9(3):277-84.
5. Davis JM, Chen N. Choice of maintenance medication for schizophrenia. J Clin Psychiatry. 2003;64 Suppl 16:24-33.
6. Bechelli LPC. Antipsicóticos de ação prolongada no tratamento de manutenção da esquizofrenia. Parte I - Fundamentos do seu desenvolvimento, benefícios e nível de aceitação em diferentes países e culturas. Rev Lat Am Enferm. 2003;11(4):507-15.
7. Leite SN, Vasconcellos MPC. Adesão à terapêutica medicamentosa: elementos para a discussão de conceitos e pressupostos adotados na literatura. Cad Saúde Coletiva. 2003;8(3):775-82.
8. Rigueira Garcia AL. Cumplimiento terapéutico: ¿qué conocemos de España?. Aten Primaria. 2001;27(8):559-68.
9. Kurita GP, Pimenta CAM. Adesão ao tratamento da dor crônica e o locus de controle da saúde. Rev Esc Enferm USP. 2004;38 (3):254-61.
10. O'Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers [editorial]. Arch Intern Med. 2006;166(17):1802-4.
11. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16(7):473-84.
12. Hamann J, Cohen R, Leucht S, Busch R, Kissling W. Shared decision making and long-term outcome in schizophrenia treatment. J Clin Psychiatry. 2007;68(7):992-7.
13. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26(5):331-42.
14. World Health Organization (WHO). Adherence to long-term therapies: evidence for action [text on the Internet]. Geneva; 2003 [cited 2007 nov. 23]. Available from: http//www.who.int/entity/chp/knowledge/publications/adherence_report/en/index.html
15. Nyberg S, Farde L, Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate: preliminary findings. Arch Gen Psychiatry. 1997;54(10):953-8.
16. Glazer WM, Kane JM. Depot neuroleptic therapy: an underrutilized treatment option. J Clin Psychiatry. 1992;53(12): 426-33.
17. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry. 1999;60 Suppl 21:25-30.
18. Yamada K, Watanabe K, Nemoto N, Fujita H, Chikaraishi C, Yamauchi K, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006;141(1):61-9.